Catriona Waitt John
ID: UNCST-2019-R001068
|
Drug Optimisation for LMICs in Pregnant HIV mothers and their INfants: temporary switch to CAB/RPV long acting injections in postpartum period
REFNo: HS5982ES
To characterise drug exposure in breast milk, and drug transfer to infants through breastfeeding, as well as infant drug elimination.
To characterise the elimination of CAB/RPV by describing PK profiles of IM CAB/RPV LA after last injection between 48 and 96 weeks.
To establish strategies on how to safely re-establish oral ART after discontinuation of IM CAB/RPV LA at 48 weeks and switch back to daily oral ART.
To explore early postpartum PK of CAB/RPV in maternal plasma and breastmilk.
To demonstrate antiviral activity and impact on retention in HIV care of temporarily switching to CAB/RPV LA compared with continuation of daily oral ART over 48 weeks.,
|
Kampala, Kampala
|
UK |
2025-09-17 13:21:16 |
2028-09-17 |
309 |
Consenting pregnant women living with HIV |
University of CapeTown |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Ronald Bisegerwa
ID: UNCST-2022-R011022
|
Accuracy of Pulse Oximeters with Profound Hypoxia
REFNo: HS6506ES
To generate two to three evidence-based recommendations to regulatory and procurement bodies within six months of study completion to guide pulse oximeter selection for diverse populations.,To collect and contribute data on pulse oximeter accuracy across diverse skin tones to an open-access device performance database by the study’s end, enabling manufacturers to refine pulse oximeter technology and ensure equitable performance across all skin tones, especially in low-resource settings.,To replicate the UCSF Hypoxia Lab in Uganda by establishing a fully equipped and operational facility within a year to evaluate pulse oximeter accuracy across diverse skin tones and hypoxia levels.,To evaluate the accuracy of pulse oximeters under controlled hypoxic conditions in a diverse population in Uganda, with a focus on understanding and addressing disparities in device performance related to skin pigmentation.,
|
Kampala, Kololo
|
Uganda |
2025-09-12 17:03:12 |
2028-09-12 |
432 |
This study will be done on healthy male or female participants between the ages of 18-50 years. |
Association of Anesthesiologists of Uganda |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Pauline Amuge Mary
ID: UNCST-2023-R005532
|
LC-REVITALIZE – A Long Covid Repurposed Drug Study
REFNo: HS6370ES
-To assess the efficacy of repurposed drugs compared to their
respective placebos in reducing standardized symptom severity scores
in participants with Long Covid.
-To compare the symptom burden (e.g., anxiety, depression, overall
well-being) in participants with Long Covid treated with repurposed
drugs versus their respective placebos.
- To assess whether symptom burden worsens in participants with Long
Covid treated with study drugs versus placebo, specifically when
symptoms are reported across multiple scales.
- To assess changes in exercise capacity over time of participants with
Long Covid treated with study drugs versus their respective placebos.
- To measure specific Long Covid pathophysiological biomarkers of study
drugs versus their respective placebos.
|
Wakiso, Sabagabo
|
Uganda |
2025-09-12 17:00:13 |
2028-09-12 |
384 |
Adults, male and female with Long COVID |
Dr. Douglas D. Fraser- Western University |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
alice namatovu
ID: UNCST-2025-R017415
|
EVALUATION OF THE EFFECTIVENESS OF BACTERIOPHAGE COCKTAILS AGAINST MULTI-DRUG-RESISTANT BACTERIA ON PATIENTS WITH DIABETIC FOOT ULCERS ATTENDING SELECTED REFERRAL HOSPITALS IN UGANDA
REFNo: HS5652ES
Main objective:
To assess the efficacy of bacteriophages in the management of diabetic foot wounds/ulcers in animal models and among patients attending the selected referral hospitals in Uganda.
Specific Objectives
i) To determine the biological and genotypic characteristics of lytic bacteriophages against the MDR- bacteria isolated from diabetic wounds of patients.
ii) To determine the virulence genes of the bacteria isolated from DFU patients and those genes associated with antimicrobial resistance.
iii) Determine the phage receptor genes on the MDR bacteria isolated from DFU patients.
iv). To evaluate the effectiveness of the identified Bacteriophage preparation/cocktail in the healing of induced diabetic wounds in mice.
v). To evaluate the effectiveness of the identified bacteriophage preparation/cocktail in the healing of diabetic foot wounds on patients in selected referral hospitals in Uganda.
|
Kampala, Namirembe
Kampala, Nsambya
|
Uganda |
2025-09-12 16:14:57 |
2028-09-12 |
138 human participants |
The study will be conducted on patients attending the selected regional referral hospitals in Uganda diagnosed with diabetes including those having diabetic foot ulcer/wounds that are not responding to antibiotic therapy, those with diabetes and not having diabetic foot and those without diabetes but having chronic wounds.
Inclusion and exclusion criteria: All Patients of 18 years and above, male or female diagnosed with diabetes and willing to participate in the study will be included. Diabetic type will be determined clinically based on the diabetes control strategy used. Those depending on insulin for diabetes control since the time of diagnosis will be classified as having T1DM while those who had been controlled on oral anti-diabetic drugs with or without insulin will be categories as T2DM. One hundred and thirty-eight patients expected to participate in the study as cases are expected to have non traumatic DFU while the control group will include diabetic patients without DFU and non-diabetic patients with chronic foot wounds. The different groups will be matched for age and gender. The exclusion criteria will include pregnant women, patients with other diabetes other than types 1 and 2, and those with wounds limited to above the ankle joints.
|
Makerere Research and innovation Fund by the Ugandan Government |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Nazarius Tumwesigye Mbona
ID: UNCST-2019-R000664
|
WEB-BASED INTERVENTION FOR ALCOHOL AND SUBSTANCE ABUSE AMONG YOUNG UNIVERSITY STUDENTS
REFNo: SS1785ES
To assess feasibility and effectiveness of the web-based intervention for prevention and treatment of ASUD problems among youth 18-24 years attending Universities in Uganda,To develop a web-based intervention for prevention and treatment of ASUD problems among youth 18-24years attending Universities in Uganda,To establish the prevalence of ASUD problems among youth 18-24years in selected Universities,To contribute to the improvement of the quality of ASUD treatment services in Uganda among the youth through the development of a web-based intervention and assess its feasibility and effectiveness for the prevention and treatment of ASUD among University students in Uganda,
|
Kampala, Mulago
Mpigi, Nkozi
|
Uganda |
2025-09-09 8:17:25 |
2028-09-09 |
5000 |
Any student aged 18 – 24 years at any level of education from the following universities: Makerere University, Kyambogo University, Makerere University Business School (semi-independent public entity), Uganda Christian University, Uganda Martyrs University Nkozi, Kampala International University (KIU) and Ndejje University. |
Government of Uganda |
Social Science and Humanities |
Clinical Trial |
Non-degree Award |
|
Adoke Yeka
ID: UNCST-2021-R004300
|
Randomised controlled trial to assess the efficacy of artemisinin combination therapies in a setting of emerging artemisinin resistance in Uganda.
REFNo: HS6327ES
To assess the 42-day clinical and parasitological efficacy of artemether-lumefantrine (AL) and pyronaridine-artesunate (PA) for the treatment of uncomplicated P. falciparum malaria in Uganda.
|
Arua, Selected parishes
Tororo, Selected parishes
|
Uganda |
2025-09-09 16:41:47 |
2028-09-09 |
150 patients on each treatment arm per site, 600 participants in total, (300 per site, AL: 150, PA: 150). |
Febrile patients aged 6 months to 10 years with confirmed uncomplicated P. falciparum malaria. |
Infectious Diseases Research Collaboration (IDRC) |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Fred Bulamba
ID: UNCST-2020-R014888
|
PErioperative respiratory care and outcomes for patieNts Undergoing hIgh risk abdomiNal surgery
REFNo: HS2178ES
To explore the cost-effectiveness of the different treatment combinations in reducing pneumonia and SSI at pre-selected centres.,To assess the impact of both interventions on postoperative mortality at 30-days, and the effect of 80-100% FiO2 only on the re-operation rate at 30 days after surgery.,To assess whether (1) preoperative 0.2% chlorhexidine mouthwash reduces the rate of postoperative pneumonia at 30-days compared to no mouthwash, and (2) 80-100% FiO2 used during surgery reduces the rate of postoperative SSI at 30-days compared to 21-35% FiO2, amongst patients aged 10 years or over undergoing elective or emergency midline laparotomy, with an anticipated abdominal incision of ≥5cm, for any indication except caesarean section.,
|
Mbale, Hospital cell
|
Uganda |
2025-08-28 10:15:49 |
2028-08-28 |
1000 (for Uganda only) |
Patients above 10 years undergoing abdominal surgery |
Dr Birgit Whitman |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Edwin Nuwagira
ID: UNCST-2021-R013488
|
EFFICACY AND TOLERABILITY OF SHORT-COURSE INTERMITTENT INTRAVENOUS LIPOSOMAL AMPHOTERICIN B VERSUS ORAL POSACONAZOLE FOR CHRONIC PULMONARY ASPERGILLOSIS: A PHASE IIA, PROSPECTIVE, MULTI-CENTRE, RANDOMIZED, CONTROLLED, OPEN-LABEL, FEASIBILITY TRIAL
REFNo: HS6400ES
5. Assess recruitment and retention of patients with CPA on a trial to inform design and sample size for a definitive efficacy trial.,4. To assess adherence to posaconazole therapy,3. To evaluate the utility of different trial endpoints (change in Aspergillus IgG antibody titer, radiological improvement, step test and weight) across groups.,2. To compare 12-month all-cause mortality in each arm,1. To measure emergence of isolates of Aspergillus with resistance/reduced susceptibility to posaconazole in both arms. ,1. Compare the efficacy and tolerability of 1) short course, high dose of intravenous liposomal amphotericin B, 2) short course, high dose of intravenous liposomal amphotericin B followed by daily posaconazole, or 3) posaconazole alone for the treatment of CPA for 6 months.,
|
Mbarara, Medical cell
Gulu, Medical cell
Kampala, Salama road
|
Uganda |
2025-08-26 13:48:03 |
2028-08-26 |
120 |
Adults, age > or = to 18 years
All Ugandan tribes living in Ankole/Kigezi sub region
Both women and men |
Fungal Infection Trust |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
RACHEL LUWAGA
ID: UNCST-2024-R003040
|
EFFECT OF A DISCHARGE EDUCATION INTERVENTION ON PREVENTION OF
PUERPERAL SEPSIS AMONG MOTHERS WHO HAVE DELIVERED BY CESAREAN
SECTION IN SOUTHWESTERN UGANDA
REFNo: HS5504ES
. To determine the prevalence, factors, and outcomes associated with readmission of
mothers who had undergone cesarean section delivery due to sepsis in Mbarara Regional
Referral Hospital
2. To describe the experiences and practices of mothers in the prevention of puerperal sepsis
post cesarean section in Mbarara Regional Referral Hospital
3. To explore the barriers and facilitators to the provision of discharge instructions
regarding puerperal sepsis prevention for mothers who have delivered by cesarean
section in Mbarara Regional Referral Hospital
4. To determine the effect of a discharge education intervention in the prevention of puerperal of
sepsis in post-cesarean section mothers.
|
Mbarara, Kamukuzi
|
Uganda |
2025-08-18 13:28:40 |
2028-08-18 |
8-10 mother with peurperal sepsis,8-10 health workers, 130 pr |
mothers diagnosed with puerperal sepsis after cesarean section delivery
Health workers working on the obstetric and gynecology ward
Primipara mothers who have delivered by cesarean section |
self sponsorship |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
Claire Nimusiima
ID: UNCST-2025-R017994
|
Assessing the association Between Disability and Mental Health among older adults: A Secondary Data Analysis of the Health and Wellbeing of Older People - Wave 5 study in Uganda.
REFNo: HS6244ES
Primary Objective
To assess the association between disability and mental health outcomes among older adults in Uganda.
Secondary Objectives
- To determine the prevalence of mental health disorders among older adults with and without disabilities.
- To explore whether any socio-demographic factors modify the association between disability and mental health outcomes.
- To assess whether HIV status confounds the association between disability and mental health outcomes.
|
Not Applicable (N/A), Not Applicable
|
Uganda |
2025-08-08 13:49:11 |
2028-08-08 |
588 |
The WOPS V study population consists of older adults (aged 50 years and above), including both HIV-positive individuals on ART and HIV-negative individuals. In Wave 5, 588 participants were surveyed.
The WOPS study was conducted in 3 districts in Uganda: Masaka, Kalungu, and Wakiso. Participants are recruited from rural, peri-urban, and urban settings, including community health centers and HIV care clinics. The study was coordinated by the MRC/UVRI & LSHTM Uganda Research Unit.
It is this study population that shall be included in the "Assessing the association Between Disability and Mental Health among older adults: A Secondary Data Analysis of the Health and Wellbeing of Older People - Wave 5 study in Uganda" study |
No funding is available for this proposed research as this is going to use already existing dataset. However, the WOPSV study was sponsored by National Institutes of Ageing, USA, through World Health Organization Study on Global Ageing and Adult Health (SAGE) |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
David Meya Bisagaya
ID: UNCST-2019-R000837
|
A Phase 2 Novel Antimicrobial Combination Therapy to Treat Tuberculous Meningitis
REFNo: HS5711ES
1. Assess the safety and efficacy of a novel anti-TB combination regimen with greater bactericidal activity than current standard of care (SOC) therapy
|
Kampala, all parishes
Mbarara, all parishes
|
Uganda |
2025-07-18 14:05:06 |
2028-07-18 |
150 |
All adults with TBM meningitis (definite, probable) with HIV, per the uniform TBM case definition. |
Meningitis Foundation |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Felix Magala
ID: UNCST-2024-R016043
|
Incidence of Post-Operative Sore Throat Among Patients Undergoing Open Abdominal Surgery: A Randomized Control Trial Comparing Video and Direct Laryngoscopy
REFNo: HS5685ES
To compare the incidence of POST, and recovery from POST following intubation using Video laryngoscopy or Direct laryngoscopy during general anaesthesia among general surgery patients undergoing laparotomy at MRRH
1. To determine the incidence of POST in the first 24 hours following intubation with either Video-laryngoscopy or Direct-laryngoscopy for patients undergoing open abdominal surgery at MRRH
2. To determine the recovery time from POST among patients intubated with Video laryngoscopy compared to Direct-laryngoscopy.
3. To describe the symptoms associated with POST amongst patients intubated for open abdominal surgery
|
Mbarara, Mbarara
|
Uganda |
2025-07-11 18:00:56 |
2028-07-11 |
148 |
Study population
We will recruit surgical patients scheduled for laparotomy (open abdominal surgery, requiring an incision of at least 5cm) at the surgical and emergency ward of MRRH.
Eligibility criteria
We shall include;
• General surgery patients scheduled for laparotomy under general anaesthesia.
• Aged 18 years and above.
• ASA class I to III.
• Mallampati class I to II.
We shall exclude:
• Have had an upper respiratory tract infection or have had an endoscopy or bronchoscopy procedure in the past 2 weeks.
• Have had any ENT, neck or thoracic surgery in past 3 months.
• Those who have symptoms of gastroesophageal reflux disease (GERD).
• And those with history of smoking.
• Those with anatomical abnormality in the neck, head, face.
• Edentulous patient.
• Patients with suspected difficult airway as assessed by the principal investigator.
|
self sponsored |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
Daniel Atwine
ID: UNCST-2019-R012948
|
SAFETY AND EFFICACY OF THE PHOTO-KABADA DEVICE AS COMPARED TO DEVICES IN ROUTINE USE IN ADMINISTERING PHOTOTHERAPY FOR BABIES WITH NEONATAL JAUNDICE: AN OPEN-LABEL, RANDOMIZED CONTROLLED CLINICAL TRIAL (MUST-2024-1404).
REFNo: HS5411ES
5) Secondary: To describe the experiences of health workers using the test (Photo-Kabada) and control PT devices and caretakers of children treated with these devices.,4) Secondary: To compare the other safety and efficacy outcomes when babies are treated with Photo-Kabada compared to available phototherapy devices on the neonatal unit of MRRH. ,3) Secondary: To compare the reduction in bilirubin levels per unit time when babies are treated with Photo-Kabada compared to available phototherapy devices on the neonatal unit of MRRH. ,2) Primary: To compare the efficacy of Photo-Kabada phototherapy machine with existing phototherapy machine at selected hospitals in treating neonates with jaundice.,1) Primary: To compare the safety of Photo-Kabada phototherapy machine with existing phototherapy machine at selected hospitals in treating neonates with jaundice.,
|
Mbarara, Nyamitanga
|
Uganda |
2025-07-10 11:09:52 |
2028-07-10 |
30 |
neonates less than 28 days old. Both male and female. |
Villgro Africa |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Esther Cathlyn Atukunda
ID: UNCST-2022-R009265
|
Evaluating Healthy Families PrEP: an intervention to promote PrEP use during periconception, pregnancy and postpartum periods for women in rural Uganda
REFNo: HS6117ES
1. Adapt Healthy Families-PrEP (HF-PrEP) to community clinics in Mbarara and Sheema Districts, Uganda to include postpartum women guided by our conceptual framework and the Consolidated Framework for Implementation Research (CFIR
2. Test Healthy Families-PrEP intervention effectiveness in a cluster-randomized control trial in Ugandan community health centers (HCs)
3. Determine incremental cost-per-person participating in Healthy Families-PrEP and estimate cost-effectiveness per incident HIV infection averted among women and their infants.
|
Mbarara, All parishes
Sheema, All parishes
|
Uganda |
2025-07-09 16:14:46 |
2028-07-09 |
approximately 700 women |
There will be two groups of participants engaged for these studies:
1) women ages 18-45 years, in periconception, pregnant, and postpartum periods seeking health services from the community health centers
2) healthcare providers, administrators, and Ministry of Health officials
|
National Institute of Health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Laura Nsangi Joan
ID: UNCST-2025-R016715
|
ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAse
REFNo: HS6040ES
The primary objective is to determine if valganciclovir is safe and efficacious in reducing CMV viraemia amongst hospitalised adults with advanced HIV disease and CMV viraemia.
Secondary objectives are to determine the effect of valganciclovir on mortality, to study its pharmacokinetics and explore the immunological response of patients with CMV viraemia before and after treatment with valganciclovir.
|
Kampala, Mulago
|
Uganda |
2025-07-04 14:08:02 |
2028-07-04 |
150 |
Adults and adolescents (≥ 15 years) diagnosed with advanced HIV disease and CMV viraemia, with a CD4 count ≤ 100 cells/μL and CMV viral load >500 IU/mL. |
Wits Health Consortium |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Sam Ononge
ID: UNCST-2020-R000328
|
A CLINICAL TRIAL TO EVALUATE THE PERFORMANCE AND SAFETY OFTHE WEKEBERE SYSTEM FOR MONITORING FETAL WELLBEING DURING LABOUR
REFNo: HS3407ES
The overall objective of this study is to demonstrate safety and performance of wekebere fetal monitoring system.
Specific Objectives
To determine accuracy of wekebere fetal monitoring in comparison with gold standard. To determine the safety of wekebere system
To determine’ uterine contractions
|
Kampala, Kawempe
|
Uganda |
2025-06-30 9:35:11 |
2028-06-30 |
120 |
The study population will consist of the following inclusion criteria: i.Female age between: 18-50
ii.Gestational age >36 + 0 weeks iii.Singleton pregnancy
iv.Early labor (cervical dilatation of <6cm)
v.Sign informed consent |
Villgro Africa |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Peter Elyanu James
ID: UNCST-2021-R013210
|
OPTIMAH Study: OPTImizing Malaria And HIV treatment in a shifting landscape in Africa
REFNo: HS6165ES
PRIMARY OBJECTIVES
1. Assess the impact of HIV/DTG on weight gain (BMI) in Ugandan children ages 5 to 17 years of age over two years of follow-up.
2. Assess for PK drug-drug interactions between the two most widely used ACTs
(AL or AS-AQ) and DTG in longitudinal cohorts of HIV-uninfected children and CLHIV living in a high endemic malaria region (Busia).
3. To assess the 28- and 42-day efficacy of AL and AS-AQ for the treatment of uncomplicated malaria in children with and without HIV in a setting where artemisinin resistance has emerged.
SECONDARY OBJECTIVES
1. To assess the impacts of DTG on changes in body composition, waist circumference, and metabolic derangements over 2-years of longitudinal follow-up.
2. To assess the impact of repeated malaria infection on changes in weight gain in CLHIV on DTG (comparing HIV-infected cohorts in Busia and Kampala).
3. To determine if changes in DTG PK exposure in the presence of repeated courses of ACTs are associated with impacts on virologic control (pharmacodynamics).
4. To assess for the development of dolutegravir-associated resistance mutations over two years of follow-up.
5. To determine if changes in ACT exposure in the presence of daily DTG for HIV treatment are associated with impacts on malaria treatment outcomes.
6. To critically compare the PK exposure of artemether, artesunate, and DHA in the context of the two leading ACTs in Africa and assess for associations between the PK exposure of artemisinin derivatives as drivers of parasitologic outcomes such as parasite clearance rates for artemisinin-sensitive and resistant infections.
7. To assess levels of gametocytemia in children with and without HIV infection and with artemisinin-sensitive and -resistant infections
8. To determine if repeated course of AL and AS-AQ are associated with selection of resistance-associated mutations to the partner drugs and/or the artemisinin component.
9. To identify novel mutations in known and/or putative loci associated with resistance to artemisinins, lumefantrine, and amodiaquine using amplicon-based sequencing and/or other genotyping methods.
10. To assess the exposure of unbound DTG, lumefantrine, and DEAQ and association with clinical outcomes (viral load or parasitemia)
|
Busia, All Parishes
Kampala, Mulago
|
Uganda |
2025-06-26 23:59:42 |
2028-06-26 |
380 |
CLHIV, ages 5-17 years, will be identified from respective registers at Baylor-Uganda (in Kampala) and the Masafu HIV clinic (and nearby clinics) in Busia Uganda. HIV-uninfected children, also ages 5-17 years, will be enrolled from catchment areas at these two sites. Recruitment will be balanced by age and sex. |
The National Institute of Child Health and Human Development |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Jolly Kamugisha G.K.
ID: UNCST-2023-R005715
|
Performance and Factors Affecting the Implementation of the Integrated Management of Acute Malnutrition Programme: A Study of Kampala, Mukono, Wakiso and Kayunga Districts
REFNo: HS6084ES
5. To document the lessons learnt and best practices during implementation of the IMAM program in the four target districts during the calendar year 2022 and 2023.,4. To establish factors that affect the utilization of IMAM services in the four target districts.,3. To determine factors influencing treatment outcomes of children with wasting in the four target districts.,2. To determine the performances of the integrated management of acute malnutrition program in the four target districts during the calendar year 2022 and 2023.,1. To identify the communities contributing to a high burden of childhood wasting caseload in health facilities in four target districts (Kampala, Mukono, Wakiso and Kayunga),The overall objective of this study is to assess the nutrition service delivery and factors influencing utilization of the IMAM programme in Kampala, Mukono, Wakiso and Kayunga districts,
|
Kampala,
Mukono,
Wakiso,
Kayunga,
|
Uganda |
2025-06-20 8:41:29 |
2028-06-20 |
Sample size varies by objective as follows: Objective 1: 1440 records; Objectives 3-5: 5 key informants ()KIIs) at policy level; 8 KIIs - district and facility administrators; 7 KIIs for health workers at facility level. |
1) Children aged < 5years with acute malnutrition - both boys and girls (Records review)
2) Caregivers of children treated acute malnutrition (both females and males aged 18+years)
3) Village Health Teams (both males and females adults aged 18+ years)
4) Health workers caring for children with acute malnutrition (Male and females aged 18+ years; District and health facility administrators (male and female aged 18years
5) Policy level stakeholders, both male and female aged 18+ years)
|
UNICEF |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Fred Ssewamala
ID: UNCST-2020-R014060
|
Suubi4PrEP: Improving PrEP Access and Adherence Among Adolescent Girls and Young Women in Uganda
REFNo: SS3990ES
Suubi4PrEP will examine the effect of a multilevel intervention, combining HIV risk reduction that incorporates sessions on PrEP, peer supporters with lived experiences to facilitate linkage to and continued care, and economic empowerment components targeting financial barriers associated with PrEP access, PrEP initiation, uptake and adherence among AGYW in Uganda. Study aims are:
Aim 1: Examine the impact of Suubi4PrEP on PrEP initiation (primary outcome); and PrEP adherence (secondary outcome).
Aim 2: Examine the effect of Suubi4PrEP on hypothesized mechanisms of change (financial stability, PrEP stigma, self-efficacy, depressive symptoms, and social support) and intervention mediation.
Aim 3: Use mixed methods to explore multi-level factors that influence PrEP initiation and adherence.
Aim 4: Assess the cost and cost-effectiveness of the interventions.
|
Masaka, Nyendo
Lwengo, Kinoni
Kyotera, Kakuuto
Kalungu, Bukulula
Rakai, Kakuuto
Sembabule, Sembabule TC
Bukomansimbi, Mbiriizi
|
Uganda |
2025-06-20 7:41:25 |
2028-06-20 |
600 |
The target study population for the proposed Suubi4PrEP study is AGYW (15-24 years) living in HIV hotspots in the greater Masaka region of Uganda.
Emancipated minors (below 18 years) will not need parental/caregiver consent. In Uganda, the National Guidelines for Research Involving Humans as Research Participants (NGHRP) define a child as any person below the age of 18. On the other hand, an emancipated minor is defined as an individual below the age of 18 who are pregnant, married, have a child, or are self-sufficient.
Inclusion Criteria. Female between 15-24 years. AGYW will be screened for HIV risk as determined by the national risk screening tool developed by the Uganda National AIDS Control Program, in alignment with national PrEP guidelines. AGYW will be deemed to be at substantial risk, and eligible to participate in the study, if they report at least one of the seven high-risk sexual behaviors on the risk assessment tool.
Exclusion criteria. A participant will be excluded if they are: 1) HIV Positive, 2) unable to understand the study procedures and/or participant rights during the informed consent process, or 3) they are unwilling or unable to commit to completing the study. If the potential participant has emergency needs (e.g., hospitalization), they will be referred for care instead.
Peer Supporters. These will be women who are HIV negative, enrolled and adhering to PrEP. We expect to recruit at least four peer supporters at each of the 20 sites receiving the PS intervention component.
|
National Institute for Mental Health |
Social Science and Humanities |
Clinical Trial |
Non-degree Award |
|
Denis Nansera
ID: UNCST-2024-R004002
|
Improving HIV testing among Children under five in Rural Uganda
REFNo: HS5829ES
The main objective of this study is to develop a traditional healer facilitated paediatric HIV testing program to improve access to paediatric HIV testing. To do this, we will first use qualitative study methods to determine factors that influence HIV testing among paediatric clients of TH and guide adaptation of the TH-facilitated HIV testing program for children. We will then implement a pilot study to evaluate offering paediatric HIV testing at traditional healer locations in southwestern Uganda.
|
|
Uganda |
2025-05-29 17:12:49 |
2028-05-29 |
465 |
Aim 1: Key stakeholders for Aim 1 will be defined as 1) adult caretakers of children ≤5 years old who receive care from TH in Mbarara District; 2) TH who care for more than 15 children under five each month; and 3) paediatric HIV clinicians from surrounding Health Centres III and IV. All participants will be 18 years or older, and able to provide informed consent. HIV clinicians must also have been in a patient-facing position (doctor, nurse, social worker, counsellor) for at least one year at the time of enrolment.
Aim 2: The study population will be ten TH with monthly volume of 15 children five years old or younger, and 200 children 18 months to 5 years of age who receive care from these TH practices in Mbarara District. Inclusion criteria for TH: aged 18 or older, consent to recruitment of children at their practice, agree with goals of the study and associated procedures, and agree to attend all study-related training. Exclusion criteria will be the same as in Aim 1 above. Inclusion criteria for children are: 18 months to 5 years old; have a parent or caregiver who can provide informed consent; not previously tested for HIV in the past three months; and not previously known to be HIV-infected. |
National Institute of Mental Health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|
